Peripheral T-Cell Lymphoma market is expected to grow at moderate rate, driven by the increasing prevalence and expected launch of new therapies by major companies
iCrowdNewswire
Jun 14, 2021
DelveInsight’s Peripheral T-Cell Lymphoma Report delivers an in-depth understanding of the Peripheral T-Cell Lymphoma, historical and forecasted epidemiology, and the Peripheral T-Cell Lymphoma market trends in the United States EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some Key Highlights from the Peripheral T-Cell Lymphoma Market Report
- In 2020, the total incident population of Peripheral T-Cell Lymphoma (PTCL) in the seven global markets was 17,057, with this number projected to increase over the forecast period.
- PTCL is divided into four stages based on the affected area: Stage I, Stage II, Stage II, Stage III, and Stage IV. Stage I, stage II, stage III, and stage IV. PTCL incident cases in the United States were 929, 771, 1,522, and 3,261, respectively, in 2020.
- Emerging therapy in the PTCL market include Copictra (Duvelisib) (Secura Bio), Tislelizumab (BeiGene), Keytruda (Merck Sharp & Dohme Corp), SP-02 (Darinaparsin, ZIO-101) (Solasia Pharma), HBI-8000 (HUYA Bioscience International/Quintiles), Azacitidine (CC-486) (Celgene Corporation), Tipifarnib (Kura Oncology), AFM13 (Affimed GmbH), Masitinib (AB Science), other.
- Major companies in the PTCL market are Secura Bio, BeiGene, Merck Sharp & Dohme Corp, Solasia Pharma, HUYA Bioscience International/Quintiles, Celgene Corporation, Kura Oncology, Affimed GmbH, AB Science, among others.
- The rise in Peripheral T-Cell Lymphoma Market Size is due to an increase in the incidence population of Peripheral T-Cell Lymphoma (PTCL) in the 7MM population.
Request sample page @ Peripheral T-Cell Lymphoma Market Insights
The Peripheral T-Cell Lymphoma market report covers existing clinical practices, new drugs, individual therapies’ market share, and current and forecasted Peripheral T-Cell Lymphoma market sizes in the 7MM (the United States, the EU5, Germany, Italy, Spain, and France), and Japan.
Peripheral T-Cell Lymphoma: Disease Overview
Peripheral T-cell lymphoma (PTCL) is a category of aggressive lymphomas that arise from mature T-cells and natural killer (NK) cells. It accounts for 10–15 percent of all non-Hodgkin lymphomas across the world.
Nonsurgical and surgical procedures are currently available, with the nonsurgical protocol including physical therapy and medications. Surgical protocols, on the other hand, include procedures like discectomy or microdiscectomy, laminectomy or laminotomy.
Peripheral T-Cell Lymphoma Epidemiology Segmentation
- Peripheral T-Cell Lymphoma Total Incident Cases
- Peripheral T-Cell Lymphoma Stage-Specific Incident Cases
- Peripheral T-Cell Lymphoma Subtype- Specific Incident Cases
Learn more about epidemiology @ Peripheral T-Cell Lymphoma Epidemiology
Peripheral T-Cell Lymphoma Treatment Landscape
Currently, there are supportive care options available for Peripheral T-Cell Lymphoma (PTCL), such as conservative (nonsurgical) and surgical approaches. Physical exercise, Behavioural approaches, and pharmacological therapies are also included in the conservative management of Peripheral T-Cell Lymphoma (PTCL).
Only five FDA-approved products for PTCL treatments are available:
- Beleodaq (Belinostat): Acrotech Biopharma
- Istodax (Romidepsin): Celgene
- Folotyn (Pralatrexate): Acrotech Biopharma
- Arranon (Nelarabine): GlaxoSmithKline
- Adcetris (Brentuximab vedotin): Seattle Genetics
Peripheral T-Cell Lymphoma Market
The market size of PTCL in the seven major markets was found to be USD 948 Million in 2020.
In the forecasted period (2021–2030), the rapid shift in the market is primarily due to the launch of Adcetris, as well as the extensive clinical pipeline and the upcoming launch of emerging therapies such as Azacitidine (CC-486), COPIKTRA (Duvelisib), and others.
Peripheral T-Cell Lymphoma Pipeline Therapies and Key Companies
- Copictra (Duvelisib): Secura Bio
- Tislelizumab: BeiGene
- Keytruda: Merck Sharp & Dohme Corp
- SP-02 (Darinaparsin, ZIO-101): Solasia Pharma
- HBI-8000: HUYA Bioscience International/Quintiles
- Azacitidine (CC-486): Celgene Corporation
- Tipifarnib: Kura Oncology
- AFM13: Affimed GmbH
- Masitinib: AB Science
Gain more knowledge about emerging drugs @ Peripheral T-Cell Lymphoma Emerging Drugs and Companies
Peripheral T-Cell Lymphoma Market Drivers
- Use of Combination Therapies
- Upcoming novel therapies in pipeline for the treatment of PTC
- An upsurge in Research and Development
Peripheral T-Cell Market Barriers
- Low rates of incidence
- Less expertise in diagnosis and rarity of PTCL subtypes
- Lack of awareness
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)
Study Period: 2018-30
PTCL Key Companies: Secura Bio, BeiGene, Merck Sharp & Dohme Corp, Solasia Pharma, HUYA Bioscience International/Quintiles, Celgene Corporation, Kura Oncology, Affimed GmbH, AB Science, among others.
PTCL Pipeline Therapies: Copictra (Duvelisib) (Secura Bio), Tislelizumab (BeiGene), Keytruda (Merck Sharp & Dohme Corp), SP-02 (Darinaparsin, ZIO-101) (Solasia Pharma), HBI-8000 (HUYA Bioscience International/Quintiles), Azacitidine (CC-486) (Celgene Corporation), Tipifarnib (Kura Oncology), AFM13 (Affimed GmbH), Masitinib (AB Science), other.
PTCL Market Segmentation: By Geography, By PTCL Therapies
Analysis: Comparative and conjoint analysis of PTCL emerging therapies
SWOT
Cases Studies
KOL’s Views
Analyst’s Views
For more information visit Peripheral T-Cell Lymphoma Market Insight Report
Table of Contents
1. | Key Insights |
2. | Executive Summary of Peripheral T-cell Lymphoma (PTCL) |
3. | Peripheral T-cell Lymphoma (PTCL) Market Overview at a Glance |
4. | Disease Background and Overview: Peripheral T-cell Lymphoma (PTCL) |
5. | PTCL: Case Reports |
6. | PTCL: Epidemiology and Patient Population |
7. | United States Epidemiology |
8. | EU5 Epidemiology |
9. | Japan Epidemiology |
10. | PTCL: Treatment |
11. | PTCL: Unmet needs |
12. | PTCL: Marketed Drugs |
13. | PTCL: Emerging Drugs |
14. | Peripheral T-cell Lymphoma (PTCL): Seven Major Market Analysis |
15. | CD30 expression in peripheral T-cell lymphomas |
16. | Expected Launch Year of Emerging Therapies of PTCL |
17. | Attribute Analysis Phase III |
18. | Attribute Analysis Phase II |
19. | United States Market Outlook |
20. | EU-5 Market Outlook |
21. | Japan Market Outlook |
22. | PTCL: Market Drivers |
23. | PTCL: Market Barriers |
24. | SWOT Analysis |
25. | Reimbursement and Market Access |
26. | Recognized Establishments |
27. | Appendix |
28. | DelveInsight Capabilities |
29. | Disclaimer |
30. | About DelveInsight |
Know more about report offerings @ Peripheral T-Cell Lymphoma Market
Related Reports
Diabetic Peripheral Neuropathy Market
Get comprehensive historical and forecast analysis of Diabetic Peripheral Neuropathy Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Helixmith, Novaremed Ltd., Grünenthal GmbH, Aptinyx, among others.
Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market
DelveInsight’s “Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD), historical and forecasted epidemiology as well as the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Peripheral Nerve Injuries Market
Get comprehensive historical and forecast analysis of Peripheral Nerve Injuries Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Toyobo, Polyganics, Axogen Corporation, Neuraptive Therapeutics, among others.
Peripheral Neuropathic Pain Market
DelveInsight’s “Peripheral Neuropathic Pain – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Peripheral Neuropathic Pain, historical and forecasted epidemiology as well as the Peripheral Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Peripheral SpA Market
DelveInsight’s “Peripheral SpA – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Peripheral SpA, historical and forecasted epidemiology as well as the Peripheral SpA market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Peripheral Vascular Interventions Market
DelveInsight’s “Peripheral Vascular Interventions – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Peripheral Vascular Interventions , historical and forecasted epidemiology as well as the Peripheral Vascular Interventions market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Chemotherapy-Induced Peripheral Neuropathy Market
DelveInsight’s ‘Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CIPN in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
Chronic Periodontitis Market
DelveInsight’s “Chronic Periodontitis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Periodontitis, historical and forecasted epidemiology as well as the Chronic Periodontitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Adult T-Cell Leukemia-Lymphoma Market
DelveInsight’s “Adult T-Cell Leukemia-Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Adult T-Cell Leukemia-Lymphoma , historical and forecasted epidemiology as well as the Adult T-Cell Leukemia-Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Natural Killer T Cell Lymphoma Market
DelveInsight’s “Natural Killer T Cell Lymphoma (NKTL) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Natural Killer T Cell Lymphoma (NKTL), historical and forecasted epidemiology as well as the Natural Killer T Cell Lymphoma (NKTL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Get in touch with our Business executive @ Lymphoma Disease Market Insights to know more
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Information:
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Connect With Us at:
LinkedIn | Facebook | Twitter